Summary

The pulmonary fibrosis treatment market is on a promising growth trajectory, driven by advancements in therapeutic approaches and an increasing focus on improving patient outcomes. Monotherapy, as a significant segment, is projected to hold a substantial market share, reflecting the ongoing shift towards more targeted and effective treatment options. In 2024, the market is projected to reach USD 3.24 billion, with expectations to rise to USD 5.07 billion by 2031, reflecting a compound annual growth rate (CAGR) of 6.60%.This market is gaining momentum as it contributes notably to the broader chronic obstructive pulmonary disease (COPD) treatment Analysis.

Sales Analysis of Pulmonary Fibrosis Treatment Market

The pulmonary fibrosis treatment market has witnessed a steady growth rate in recent years, reflecting the growing recognition of this serious condition and the increasing efforts to manage it effectively. Pulmonary fibrosis is characterized by scarring of lung tissue, leading to reduced lung capacity and difficulty in oxygen exchange. While it remains an incurable disease, advancements in drug therapies have significantly improved the management of the condition, helping to extend patient survival and enhance quality of life.

In recent years, research in the western world has intensified, with numerous studies focused on understanding the underlying causes of pulmonary fibrosis and exploring potential breakthrough therapies. Many academic institutions, along with pharmaceutical and biopharmaceutical companies, are actively working on developing innovative treatment pathways. For instance, the launch of research aimed at supporting precision medicine for idiopathic pulmonary fibrosis (IPF) marked a significant step forward in the quest for more personalized treatment options. This research, supported by substantial grants, aims to isolate and examine specific genetic and molecular factors, paving the way for novel therapies.

Additionally, regulatory initiatives, such as the U.S. FDA orphan drug designation program, have played a crucial role in fostering innovation in pulmonary fibrosis treatment. This program provides incentives, including market exclusivity, tax credits, and federal grants, to encourage the development of therapies for rare diseases like pulmonary fibrosis. Companies that have received orphan drug designation for their products have benefited from these incentives, which have accelerated the development and commercialization of new therapies.

Market Drivers and Growth Opportunities

One of the key drivers of growth in the pulmonary fibrosis treatment market is the increasing number of drug approvals and launches. Drug manufacturers are focused on building robust pipelines, with a particular emphasis on improving patient compliance and outcomes. The development of novel therapies, including biologics, is expected to drive significant growth in the market. Manufacturers are engaging in various research activities and seeking regulatory approvals across different regions to expand their market presence and generate revenue.

For example, breakthrough therapy designations and orphan drug designations for drugs targeting pulmonary fibrosis have led to accelerated development and approval processes. These designations not only highlight the potential of these drugs but also increase their adoption rates, thereby contributing to market growth. Several companies are also exploring strategic acquisitions and collaborations to expand their product portfolios and enhance their regional presence, particularly in emerging markets.

Challenges and Restraints

Despite the promising outlook, the pulmonary fibrosis treatment market faces certain challenges that could impact its growth. The limited range of treatment options remains a significant barrier to effective disease management. Until recently, off-label use of immunosuppressive drugs was the primary approach to treating pulmonary fibrosis. However, the introduction of new drugs has revolutionized treatment in developed countries, offering patients more targeted and effective therapies.

The high cost of these drugs, combined with lower per capita spending on pulmonary fibrosis treatment in many regions, poses a challenge to market growth. Additionally, limited availability of advanced treatment options in low- and middle-income countries further restricts market potential. Patients in these regions often receive diagnoses at later stages of the disease, leading to higher rates of comorbidities and complicating treatment. Comorbidities, such as pulmonary hypertension, are prevalent in a significant proportion of pulmonary fibrosis patients, adding another layer of complexity to disease management.

Regional Market Insights

In the U.S., the pulmonary fibrosis treatment market is experiencing robust growth, driven by the increasing prevalence of pulmonary disorders. Smoking remains a major risk factor, contributing to the rising incidence of pulmonary fibrosis. Although smoking rates have declined, the large population base has resulted in a substantial number of smokers, both active and passive, thereby sustaining the demand for pulmonary fibrosis treatments.

Germany, as a leading market in Europe, continues to see high adoption rates of pulmonary fibrosis treatments. The country’s aging population, combined with industrial advancements and increased research and development spending, is driving demand for effective therapies. The risk of pulmonary fibrosis increases with age, making the growing geriatric population a significant factor in the market's growth.

Japan is emerging as a prominent market for pulmonary fibrosis treatment, with its large and skilled workforce supporting the outsourcing of many pharmaceutical projects. The country’s strong pharmaceutical industry and government support for healthcare initiatives have created a favorable environment for market growth. Japan’s role as a major export market for pharmaceuticals further enhances its significance in the global pulmonary fibrosis treatment Analysis.

Segment Analysis

The monotherapy segment dominates the pulmonary fibrosis treatment market, reflecting the widespread use of single-drug therapies. Monotherapy offers several advantages, including the absence of drug interactions, lower costs, and reduced side effects. Drugs such as pirfenidone, nintedanib, and corticosteroids are commonly used as monotherapy options, contributing significantly to market growth.

Idiopathic pulmonary fibrosis (IPF) remains the most common indication for pulmonary fibrosis treatment, with a large number of patients requiring ongoing therapy. The high incidence of IPF and its severe impact on patient health drive the demand for effective treatments. The use of high-quality and biologically compatible materials in these therapies further supports market growth.

Retail pharmacies are the primary distribution channel for pulmonary fibrosis treatments, accounting for a significant share of the market. The easy availability of prescription drugs and over-the-counter medications in retail pharmacies ensures that patients have access to the treatments they need. This distribution channel is expected to maintain its leading position, driven by the increasing demand for pulmonary fibrosis therapies.

Competitive Analysis

The competitive Analysis of the pulmonary fibrosis treatment market is characterized by consolidation activities such as mergers and acquisitions, as well as corporate collaborations aimed at expanding market presence. Leading players in the industry are actively involved in research and development efforts to introduce new and improved therapies.

For instance, the launch of a generic version of nintedanib for the treatment of IPF in India highlights the ongoing efforts of pharmaceutical companies to expand their product offerings and reach new markets. The introduction of this drug in various formulations is expected .

Key Companies Profiled

• F. Hoffman - La Roche Ltd.

• Boehringer Ingelheim

• International GmbH

• Cipla Ltd (Cipla)

• Gilead Sciences, Inc.

• Bristol-Myers Squibb Company

• FibroGen Inc.,

• Galecto, Inc.

Key Segments Covered in Pulmonary Fibrosis Treatment Industry Research

By Therapy Type:

• Monotherapy

o Pirfenidone Therapy

o Nintedanib Therapy

o Corticosteroids Therapy

• Combination Therapy

o Pirfenidone & Corticosteroid

o Nintedanib & Corticosteroid

o Pirfenidone & Antitussive

o Others

• Symptomatic Treatment

By Indication:

• Idiopathic Pulmonary Fibrosis (IPF)

• Familial PF

• Others

By Distribution Channel:

• Hospital Pharmacy

• Retail Pharmacy

• Mail Order Pharmacy

By Region:

• North America

• Latin America

• Europe

• South Asia

• East Asia

• Oceania

• Middle East & Africa

ページTOPに戻る

Table of Contents

1. Executive Summary
1.1. Global Pulmonary Fibrosis Treatment Market Snapshot
1.2. Future Projections
1.3. Key Market Trends
1.4. Regional Snapshot, by Value, 2024
1.5. Analyst Recommendations
2. Market Overview
2.1. Market Definitions and Segmentations
2.2. Market Dynamics
2.2.1. Drivers
2.2.2. Restraints
2.2.3. Market Opportunities
2.3. Value Chain Analysis
2.4. Porter’s Five Forces Analysis
2.5. COVID-19 Impact Analysis
2.5.1. Supply
2.5.2. Demand
2.6. Impact of Ukraine-Russia Conflict
2.7. Economic Overview
2.7.1. World Economic Projections
2.8. PESTLE Analysis
3. Global Pulmonary Fibrosis Treatment Market Outlook, 2019 - 2031
3.1. Global Pulmonary Fibrosis Treatment Market Outlook, by Therapy Type, Value (US$ Bn), 2019 - 2031
3.1.1. Key Highlights
3.1.1.1. Monotherapy
3.1.1.1.1. Pirfenidone Therapy
3.1.1.1.2. Nintedanib Therapy
3.1.1.1.3. Corticosteroids Therapy
3.1.1.2. Combination Therapy
3.1.1.2.1. Pirfenidone & Corticosteroid
3.1.1.2.2. Nintedanib & Corticosteroid
3.1.1.2.3. Pirfenidone & Antitussive
3.1.1.2.4. Others
3.1.1.3. Symptomatic Treatment
3.2. Global Pulmonary Fibrosis Treatment Market Outlook, by Indication, Value (US$ Bn), 2019 - 2031
3.2.1. Key Highlights
3.2.1.1. Idiopathic Pulmonary Fibrosis (IPF)
3.2.1.2. Familial PF
3.2.1.3. Others
3.3. Global Pulmonary Fibrosis Treatment Market Outlook, by Distribution Channel, Value (US$ Bn), 2019 - 2031
3.3.1. Key Highlights
3.3.1.1. Hospital Pharmacy
3.3.1.2. Retail Pharmacy
3.3.1.3. Mail Order Pharmacy
3.4. Global Pulmonary Fibrosis Treatment Market Outlook, by Region, Value (US$ Bn), 2019 - 2031
3.4.1. Key Highlights
3.4.1.1. North America
3.4.1.2. Europe
3.4.1.3. Asia Pacific
3.4.1.4. Latin America
3.4.1.5. Middle East & Africa
4. North America Pulmonary Fibrosis Treatment Market Outlook, 2019 - 2031
4.1. North America Pulmonary Fibrosis Treatment Market Outlook, by Therapy Type, Value (US$ Bn), 2019 - 2031
4.1.1. Key Highlights
4.1.1.1. Monotherapy
4.1.1.1.1. Pirfenidone Therapy
4.1.1.1.2. Nintedanib Therapy
4.1.1.1.3. Corticosteroids Therapy
4.1.1.2. Combination Therapy
4.1.1.2.1. Pirfenidone & Corticosteroid
4.1.1.2.2. Nintedanib & Corticosteroid
4.1.1.2.3. Pirfenidone & Antitussive
4.1.1.2.4. Others
4.1.1.3. Symptomatic Treatment
4.2. North America Pulmonary Fibrosis Treatment Market Outlook, by Indication, Value (US$ Bn), 2019 - 2031
4.2.1. Key Highlights
4.2.1.1. Idiopathic Pulmonary Fibrosis (IPF)
4.2.1.2. Familial PF
4.2.1.3. Others
4.3. North America Pulmonary Fibrosis Treatment Market Outlook, by Distribution Channel, Value (US$ Bn), 2019 - 2031
4.3.1. Key Highlights
4.3.1.1. Hospital Pharmacy
4.3.1.2. Retail Pharmacy
4.3.1.3. Mail Order Pharmacy
4.3.2. BPS Analysis/Market Attractiveness Analysis
4.4. North America Pulmonary Fibrosis Treatment Market Outlook, by Country, Value (US$ Bn), 2019 - 2031
4.4.1. Key Highlights
4.4.1.1. U.S. Pulmonary Fibrosis Treatment Market by Therapy Type, Value (US$ Bn), 2019 - 2031
4.4.1.2. U.S. Pulmonary Fibrosis Treatment Market by Indication, Value (US$ Bn), 2019 - 2031
4.4.1.3. U.S. Pulmonary Fibrosis Treatment Market by Distribution Channel, Value (US$ Bn), 2019 - 2031
4.4.1.4. Canada Pulmonary Fibrosis Treatment Market by Therapy Type, Value (US$ Bn), 2019 - 2031
4.4.1.5. Canada Pulmonary Fibrosis Treatment Market by Indication, Value (US$ Bn), 2019 - 2031
4.4.1.6. Canada Pulmonary Fibrosis Treatment Market by Distribution Channel, Value (US$ Bn), 2019 - 2031
4.4.2. BPS Analysis/Market Attractiveness Analysis
5. Europe Pulmonary Fibrosis Treatment Market Outlook, 2019 - 2031
5.1. Europe Pulmonary Fibrosis Treatment Market Outlook, by Therapy Type, Value (US$ Bn), 2019 - 2031
5.1.1. Key Highlights
5.1.1.1. Monotherapy
5.1.1.1.1. Pirfenidone Therapy
5.1.1.1.2. Nintedanib Therapy
5.1.1.1.3. Corticosteroids Therapy
5.1.1.2. Combination Therapy
5.1.1.2.1. Pirfenidone & Corticosteroid
5.1.1.2.2. Nintedanib & Corticosteroid
5.1.1.2.3. Pirfenidone & Antitussive
5.1.1.2.4. Others
5.1.1.3. Symptomatic Treatment
5.2. Europe Pulmonary Fibrosis Treatment Market Outlook, by Indication, Value (US$ Bn), 2019 - 2031
5.2.1. Key Highlights
5.2.1.1. Idiopathic Pulmonary Fibrosis (IPF)
5.2.1.2. Familial PF
5.2.1.3. Others
5.3. Europe Pulmonary Fibrosis Treatment Market Outlook, by Distribution Channel, Value (US$ Bn), 2019 - 2031
5.3.1. Key Highlights
5.3.1.1. Hospital Pharmacy
5.3.1.2. Retail Pharmacy
5.3.1.3. Mail Order Pharmacy
5.3.2. BPS Analysis/Market Attractiveness Analysis
5.4. Europe Pulmonary Fibrosis Treatment Market Outlook, by Country, Value (US$ Bn), 2019 - 2031
5.4.1. Key Highlights
5.4.1.1. Germany Pulmonary Fibrosis Treatment Market by Therapy Type, Value (US$ Bn), 2019 - 2031
5.4.1.2. Germany Pulmonary Fibrosis Treatment Market by Indication, Value (US$ Bn), 2019 - 2031
5.4.1.3. Germany Pulmonary Fibrosis Treatment Market by Distribution Channel, Value (US$ Bn), 2019 - 2031
5.4.1.4. U.K. Pulmonary Fibrosis Treatment Market by Therapy Type, Value (US$ Bn), 2019 - 2031
5.4.1.5. U.K. Pulmonary Fibrosis Treatment Market by Indication, Value (US$ Bn), 2019 - 2031
5.4.1.6. U.K. Pulmonary Fibrosis Treatment Market by Distribution Channel, Value (US$ Bn), 2019 - 2031
5.4.1.7. France Pulmonary Fibrosis Treatment Market by Therapy Type, Value (US$ Bn), 2019 - 2031
5.4.1.8. France Pulmonary Fibrosis Treatment Market by Indication, Value (US$ Bn), 2019 - 2031
5.4.1.9. France Pulmonary Fibrosis Treatment Market by Distribution Channel, Value (US$ Bn), 2019 - 2031
5.4.1.10. Italy Pulmonary Fibrosis Treatment Market by Therapy Type, Value (US$ Bn), 2019 - 2031
5.4.1.11. Italy Pulmonary Fibrosis Treatment Market by Indication, Value (US$ Bn), 2019 - 2031
5.4.1.12. Italy Pulmonary Fibrosis Treatment Market by Distribution Channel, Value (US$ Bn), 2019 - 2031
5.4.1.13. Turkey Pulmonary Fibrosis Treatment Market by Therapy Type, Value (US$ Bn), 2019 - 2031
5.4.1.14. Turkey Pulmonary Fibrosis Treatment Market by Indication, Value (US$ Bn), 2019 - 2031
5.4.1.15. Turkey Pulmonary Fibrosis Treatment Market by Distribution Channel, Value (US$ Bn), 2019 - 2031
5.4.1.16. Russia Pulmonary Fibrosis Treatment Market by Therapy Type, Value (US$ Bn), 2019 - 2031
5.4.1.17. Russia Pulmonary Fibrosis Treatment Market by Indication, Value (US$ Bn), 2019 - 2031
5.4.1.18. Russia Pulmonary Fibrosis Treatment Market by Distribution Channel, Value (US$ Bn), 2019 - 2031
5.4.1.19. Rest of Europe Pulmonary Fibrosis Treatment Market by Therapy Type, Value (US$ Bn), 2019 - 2031
5.4.1.20. Rest of Europe Pulmonary Fibrosis Treatment Market by Indication, Value (US$ Bn), 2019 - 2031
5.4.1.21. Rest of Europe Pulmonary Fibrosis Treatment Market by Distribution Channel, Value (US$ Bn), 2019 - 2031
5.4.2. BPS Analysis/Market Attractiveness Analysis
6. Asia Pacific Cassava Starch Market Outlook, 2019 - 2031
6.1. Asia Pacific Cassava Starch Market Outlook, by Therapy Type, Value (US$ Bn), 2019 - 2031
6.1.1. Key Highlights
6.1.1.1. Monotherapy
6.1.1.1.1. Pirfenidone Therapy
6.1.1.1.2. Nintedanib Therapy
6.1.1.1.3. Corticosteroids Therapy
6.1.1.2. Combination Therapy
6.1.1.2.1. Pirfenidone & Corticosteroid
6.1.1.2.2. Nintedanib & Corticosteroid
6.1.1.2.3. Pirfenidone & Antitussive
6.1.1.2.4. Others
6.1.1.3. Symptomatic Treatment
6.2. Asia Pacific Pulmonary Fibrosis Treatment Market Outlook, by Indication, Value (US$ Bn), 2019 - 2031
6.2.1. Key Highlights
6.2.1.1. Idiopathic Pulmonary Fibrosis (IPF)
6.2.1.2. Familial PF
6.2.1.3. Others
6.3. Asia Pacific Pulmonary Fibrosis Treatment Market Outlook, by Distribution Channel, Value (US$ Bn), 2019 - 2031
6.3.1. Key Highlights
6.3.1.1. Hospital Pharmacy
6.3.1.2. Retail Pharmacy
6.3.1.3. Mail Order Pharmacy
6.3.2. BPS Analysis/Market Attractiveness Analysis
6.4. Asia Pacific Pulmonary Fibrosis Treatment Market Outlook, by Country, Value (US$ Bn), 2019 - 2031
6.4.1. Key Highlights
6.4.1.1. China Pulmonary Fibrosis Treatment Market by Therapy Type, Value (US$ Bn), 2019 - 2031
6.4.1.2. China Pulmonary Fibrosis Treatment Market by Indication, Value (US$ Bn), 2019 - 2031
6.4.1.3. China Pulmonary Fibrosis Treatment Market by Distribution Channel, Value (US$ Bn), 2019 - 2031
6.4.1.4. Japan Pulmonary Fibrosis Treatment Market by Therapy Type, Value (US$ Bn), 2019 - 2031
6.4.1.5. Japan Pulmonary Fibrosis Treatment Market by Indication, Value (US$ Bn), 2019 - 2031
6.4.1.6. Japan Pulmonary Fibrosis Treatment Market by Distribution Channel, Value (US$ Bn), 2019 - 2031
6.4.1.7. South Korea Pulmonary Fibrosis Treatment Market by Therapy Type, Value (US$ Bn), 2019 - 2031
6.4.1.8. South Korea Pulmonary Fibrosis Treatment Market by Indication, Value (US$ Bn), 2019 - 2031
6.4.1.9. South Korea Pulmonary Fibrosis Treatment Market by Distribution Channel, Value (US$ Bn), 2019 - 2031
6.4.1.10. India Pulmonary Fibrosis Treatment Market by Therapy Type, Value (US$ Bn), 2019 - 2031
6.4.1.11. India Pulmonary Fibrosis Treatment Market by Indication, Value (US$ Bn), 2019 - 2031
6.4.1.12. India Pulmonary Fibrosis Treatment Market by Distribution Channel, Value (US$ Bn), 2019 - 2031
6.4.1.13. Southeast Asia Pulmonary Fibrosis Treatment Market by Therapy Type, Value (US$ Bn), 2019 - 2031
6.4.1.14. Southeast Asia Pulmonary Fibrosis Treatment Market by Indication, Value (US$ Bn), 2019 - 2031
6.4.1.15. Southeast Asia Pulmonary Fibrosis Treatment Market by Distribution Channel, Value (US$ Bn), 2019 - 2031
6.4.1.16. Rest of Asia Pacific Pulmonary Fibrosis Treatment Market by Therapy Type, Value (US$ Bn), 2019 - 2031
6.4.1.17. Rest of Asia Pacific Pulmonary Fibrosis Treatment Market by Indication, Value (US$ Bn), 2019 - 2031
6.4.1.18. Rest of Asia Pacific Pulmonary Fibrosis Treatment Market by Distribution Channel, Value (US$ Bn), 2019 - 2031
6.4.2. BPS Analysis/Market Attractiveness Analysis
7. Latin America Pulmonary Fibrosis Treatment Market Outlook, 2019 - 2031
7.1. Latin America Pulmonary Fibrosis Treatment Market Outlook, by Therapy Type, Value (US$ Bn), 2019 - 2031
7.1.1. Key Highlights
7.1.1.1. Monotherapy
7.1.1.1.1. Pirfenidone Therapy
7.1.1.1.2. Nintedanib Therapy
7.1.1.1.3. Corticosteroids Therapy
7.1.1.2. Combination Therapy
7.1.1.2.1. Pirfenidone & Corticosteroid
7.1.1.2.2. Nintedanib & Corticosteroid
7.1.1.2.3. Pirfenidone & Antitussive
7.1.1.2.4. Others
7.1.1.3. Symptomatic Treatment
7.2. Latin America Pulmonary Fibrosis Treatment Market Outlook, by Indication, Value (US$ Bn), 2019 - 2031
7.2.1.1. Idiopathic Pulmonary Fibrosis (IPF)
7.2.1.2. Familial PF
7.2.1.3. Others
7.3. Latin America Pulmonary Fibrosis Treatment Market Outlook, by Distribution Channel, Value (US$ Bn), 2019 - 2031
7.3.1. Key Highlights
7.3.1.1. Hospital Pharmacy
7.3.1.2. Retail Pharmacy
7.3.1.3. Mail Order Pharmacy
7.3.2. BPS Analysis/Market Attractiveness Analysis
7.4. Latin America Pulmonary Fibrosis Treatment Market Outlook, by Country, Value (US$ Bn), 2019 - 2031
7.4.1. Key Highlights
7.4.1.1. Brazil Pulmonary Fibrosis Treatment Market by Therapy Type, Value (US$ Bn), 2019 - 2031
7.4.1.2. Brazil Pulmonary Fibrosis Treatment Market by Indication, Value (US$ Bn), 2019 - 2031
7.4.1.3. Brazil Pulmonary Fibrosis Treatment Market by Distribution Channel, Value (US$ Bn), 2019 - 2031
7.4.1.4. Mexico Pulmonary Fibrosis Treatment Market by Therapy Type, Value (US$ Bn), 2019 - 2031
7.4.1.5. Mexico Pulmonary Fibrosis Treatment Market by Indication, Value (US$ Bn), 2019 - 2031
7.4.1.6. Mexico Pulmonary Fibrosis Treatment Market by Distribution Channel, Value (US$ Bn), 2019 - 2031
7.4.1.7. Argentina Pulmonary Fibrosis Treatment Market by Therapy Type, Value (US$ Bn), 2019 - 2031
7.4.1.8. Argentina Pulmonary Fibrosis Treatment Market by Indication, Value (US$ Bn), 2019 - 2031
7.4.1.9. Argentina Pulmonary Fibrosis Treatment Market by Distribution Channel, Value (US$ Bn), 2019 - 2031
7.4.1.10. Rest of Latin America Pulmonary Fibrosis Treatment Market by Therapy Type, Value (US$ Bn), 2019 - 2031
7.4.1.11. Rest of Latin America Pulmonary Fibrosis Treatment Market by Indication, Value (US$ Bn), 2019 - 2031
7.4.1.12. Rest of Latin America Pulmonary Fibrosis Treatment Market by Distribution Channel, Value (US$ Bn), 2019 - 2031
7.4.2. BPS Analysis/Market Attractiveness Analysis
8. Middle East & Africa Pulmonary Fibrosis Treatment Market Outlook, 2019 - 2031
8.1. Middle East & Africa Pulmonary Fibrosis Treatment Market Outlook, by Therapy Type, Value (US$ Bn), 2019 - 2031
8.1.1. Key Highlights
8.1.1.1. Monotherapy
8.1.1.1.1. Pirfenidone Therapy
8.1.1.1.2. Nintedanib Therapy
8.1.1.1.3. Corticosteroids Therapy
8.1.1.2. Combination Therapy
8.1.1.2.1. Pirfenidone & Corticosteroid
8.1.1.2.2. Nintedanib & Corticosteroid
8.1.1.2.3. Pirfenidone & Antitussive
8.1.1.2.4. Others
8.1.1.3. Symptomatic Treatment
8.2. Middle East & Africa Pulmonary Fibrosis Treatment Market Outlook, by Indication, Value (US$ Bn), 2019 - 2031
8.2.1. Key Highlights
8.2.1.1. Idiopathic Pulmonary Fibrosis (IPF)
8.2.1.2. Familial PF
8.2.1.3. Others
8.3. Middle East & Africa Pulmonary Fibrosis Treatment Market Outlook, by Distribution Channel, Value (US$ Bn), 2019 - 2031
8.3.1.1. Hospital Pharmacy
8.3.1.2. Retail Pharmacy
8.3.1.3. Mail Order Pharmacy
8.3.2. BPS Analysis/Market Attractiveness Analysis
8.4. Middle East & Africa Pulmonary Fibrosis Treatment Market Outlook, by Country, Value (US$ Bn), 2019 - 2031
8.4.1. Key Highlights
8.4.1.1. GCC Pulmonary Fibrosis Treatment Market by Therapy Type, Value (US$ Bn), 2019 - 2031
8.4.1.2. GCC Pulmonary Fibrosis Treatment Market by Indication, Value (US$ Bn), 2019 - 2031
8.4.1.3. GCC Pulmonary Fibrosis Treatment Market by Distribution Channel, Value (US$ Bn), 2019 - 2031
8.4.1.4. South Africa Pulmonary Fibrosis Treatment Market by Therapy Type, Value (US$ Bn), 2019 - 2031
8.4.1.5. South Africa Pulmonary Fibrosis Treatment Market by Indication, Value (US$ Bn), 2019 - 2031
8.4.1.6. South Africa Pulmonary Fibrosis Treatment Market by Distribution Channel, Value (US$ Bn), 2019 - 2031
8.4.1.7. Egypt Pulmonary Fibrosis Treatment Market by Therapy Type, Value (US$ Bn), 2019 - 2031
8.4.1.8. Egypt Pulmonary Fibrosis Treatment Market by Indication, Value (US$ Bn), 2019 - 2031
8.4.1.9. Egypt Pulmonary Fibrosis Treatment Market by Distribution Channel, Value (US$ Bn), 2019 - 2031
8.4.1.10. Nigeria Pulmonary Fibrosis Treatment Market by Therapy Type, Value (US$ Bn), 2019 - 2031
8.4.1.11. Nigeria Pulmonary Fibrosis Treatment Market by Indication, Value (US$ Bn), 2019 - 2031
8.4.1.12. Nigeria Pulmonary Fibrosis Treatment Market by Distribution Channel, Value (US$ Bn), 2019 - 2031
8.4.1.13. Rest of Middle East & Africa Pulmonary Fibrosis Treatment Market by Therapy Type, Value (US$ Bn), 2019 - 2031
8.4.1.14. Rest of Middle East & Africa Pulmonary Fibrosis Treatment Market by Indication, Value (US$ Bn), 2019 - 2031
8.4.1.15. Rest of Middle East & Africa Pulmonary Fibrosis Treatment Market by Distribution Channel, Value (US$ Bn), 2019 - 2031
8.4.2. BPS Analysis/Market Attractiveness Analysis
9. Competitive Landscape
9.1. By Distribution Channel vs by Indication Heat map
9.2. Manufacturer vs by Indication Heatmap
9.3. Company Market Share Analysis, 2024
9.4. Competitive Dashboard
9.5. Company Profiles
9.5.1. F. Hoffman - La Roche Ltd.
9.5.1.1. Company Overview
9.5.1.2. Product Portfolio
9.5.1.3. Financial Overview
9.5.1.4. Business Strategies and Development
9.5.2. Boehringer Ingelheim
9.5.2.1. Company Overview
9.5.2.2. Product Portfolio
9.5.2.3. Financial Overview
9.5.2.4. Business Strategies and Development
9.5.3. International GmbH
9.5.3.1. Company Overview
9.5.3.2. Product Portfolio
9.5.3.3. Financial Overview
9.5.3.4. Business Strategies and Development
9.5.4. Cipla Ltd (Cipla)
9.5.4.1. Company Overview
9.5.4.2. Product Portfolio
9.5.4.3. Financial Overview
9.5.4.4. Business Strategies and Development
9.5.5. Gilead Sciences, Inc.
9.5.5.1. Company Overview
9.5.5.2. Product Portfolio
9.5.5.3. Financial Overview
9.5.5.4. Business Strategies and Development
9.5.6. Bristol-Myers Squibb Company
9.5.6.1. Company Overview
9.5.6.2. Product Portfolio
9.5.6.3. Financial Overview
9.5.6.4. Business Strategies and Development
9.5.7. FibroGen Inc
9.5.7.1. Company Overview
9.5.7.2. Product Portfolio
9.5.7.3. Financial Overview
9.5.7.4. Business Strategies and Development
9.5.8. Galecto, Inc
9.5.8.1. Company Overview
9.5.8.2. Product Portfolio
9.5.8.3. Financial Overview
9.5.8.4. Business Strategies and Development
9.5.8.5.
10. Appendix
10.1. Research Methodology
10.2. Report Assumptions
10.3. Acronyms and Abbreviations